WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: Identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers

Biochemical Pharmacology

Volumn 75, Issue 4, 2008, Pages 847-856

  Hsiao, Che Jen ^a,c   Li, Tsia Kun ^b   Chan, Ya Ling ^c   Hsin, Ling Wei ^c   Liao, Cho Hwa ^c   Lee, Chien Hua ^b   Lyu, Ping Chiang ^a   Guh, Jih Hwa ^c  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Cardiotoxicity; Cell cycle arrest; Drug resistance; Mitochondria; Topoisomerase II inhibitor

Indexed keywords

ANDROGEN; CASPASE 2; CASPASE 3; CASPASE 9; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; METHIONINE DERIVATIVE; MITOXANTRONE; PROTEIN BCL 2; PROTEIN MCL 1; SURVIVIN; UNCLASSIFIED DRUG; WRC 213;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER SCREENING; CARDIOTOXICITY; CELL ACTIVATION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN MCF 7; CHROMOSOME; COLORECTAL CANCER; COMET ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DEGRADATION; DNA DAMAGE; DNA STRAND BREAKAGE; DOWN REGULATION; DRUG ACTIVITY; DRUG CONJUGATION; DRUG INHIBITION; DRUG RESISTANCE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IC 50; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MITOCHONDRION; PRIORITY JOURNAL; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COMET ASSAY; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; MALE; METHIONINE; MITOXANTRONE; MOLECULAR STRUCTURE; MYOCYTES, CARDIAC; PROSTATIC NEOPLASMS;

EID: 38649100655     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.10.012     Document Type: Article

References (33)

1. Zijlstra J.G., de Jong S., de Vries E.G., and Mulder N.H. Topoisomerases, new targets in cancer chemotherapy. Med Oncol Tumor Pharmacother 7 (1990) 11-18
2. Malonne H., and Atassi G. DNA topoisomerase targeting drugs: mechanisms of action and perspectives. Anticancer Drugs 8 (1997) 811-822
3. Fortune J.M., and Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 64 (2000) 221-253
4. Giles G.I., and Sharma R.P. Topoisomerase enzymes as therapeutic targets for cancer chemotherapy. Med Chem 1 (2005) 383-394
5. Leonce S., Perez V., Casabianca-Pignede M.R., Anstett M., Bisagni E., Pierre A., et al. In vitro cytotoxicity of S16020-2, a new olivacine derivative. Invest New Drugs 14 (1996) 169-180
6. Hofmann G.A., and Mattern M.R. Topoisomerase II in multiple drug resistance. Cytotechnology 12 (1993) 137-154
7. Mimeault M., Venkatraman G., Johansson S.L., Moore E., Henichart J.P., Depreux P., et al. Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide. Int J Cancer 120 (2007) 160-169
8. Tedesco D., Zhang J., Trinh L., Lalehzadeh G., Meisner R., Yamaguchi K.D., et al. The ubiquitin-conjugating enzyme E2-EPF is overexpressed in primary breast cancer and modulates sensitivity to topoisomerase II inhibition. Neoplasia 9 (2007) 601-613
9. Hasinoff B.B., Abram M.E., Barnabe N., Khelifa T., Allan W.P., and Yalowich J.C. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Mol Pharmacol 59 (2001) 453-461
10. Tabata M., Tabata R., Grabowski D.R., Bukowski R.M., Ganapathi M.K., and Ganapathi R. Roles of NF-κB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma. J Biol Chem 276 (2001) 8029-8036
11. Mikhailov A., Shinohara M., and Rieder C.L. Topoisomerase II and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathway. J Cell Biol 166 (2004) 517-526
12. Kurosu T., Takahashi Y., Fukuda T., Koyama T., Miki T., and Miura O. p38 MAP kinase plays a role in G2 checkpoint activation and inhibits apoptosis of human B cell lymphoma cells treated with etoposide. Apoptosis 10 (2005) 1111-1120
13. Huang X., Kurose A., Tanaka T., Traganos F., Dai W., and Darzynkiewicz Z. Activation of ATM and histone H2AX phosphorylation induced by mitoxantrone but not by topotecan is prevented by the antioxidant N-acetyl-l-cysteine. Cancer Biol Ther 5 (2006) 959-964
14. Ravid A., Rocker D., Machlenkin A., Rotem C., Hochman A., Kessler-Icekson G., et al. 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res 59 (1999) 862-867
15. Watanabe K., Kubota M., Hamahata K., Lin Y., and Usami I. Prevention of etoposide-induced apoptosis by proteasome inhibitors in a human leukemic cell line but not in fresh acute leukemia blasts. A differential role of NF-κB activation. Biochem Pharmacol 60 (2000) 823-830
16. Sinha B.K. Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs 49 (1995) 11-19
17. Kobayashi M., Adachi N., Aratani Y., Kikuchi A., and Koyama H. Decreased topoisomerase IIα expression confers increased resistance to ICRF-193 as well as VP-16 in mouse embryonic stem cells. Cancer Lett 166 (2001) 71-77
18. Seiter K. Toxicity of the topoisomerase II inhibitors. Expert Opin Drug Saf 4 (2005) 219-234
19. Bidwell III G.L., Fokt I., Priebe W., and Raucher D. Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin. Biochem Pharmacol 73 (2007) 620-631
20. Zucchi R., and Danesi R. Cardiac toxicity of antineoplastic anthracyclines. Curr Med Chem Anticancer Agents 3 (2003) 151-171
21. Missirlis D., Kawamura R., Tirelli N., and Hubbell J.A. Doxorubicin encapsulation and diffusional release from stable, polymeric, hydrogel nanoparticles. Eur J Pharm Sci 29 (2006) 120-129
22. Jaattela M. Escaping cell death: survival proteins in cancer. Exp Cell Res 248 (1999) 30-43
23. Jiang Z.H., Zhang W.J., Rao Y., and Wu J.Y. Regulation of Ich-1 pre-mRNA alternative splicing and apoptosis by mammalian splicing factors. Proc Natl Acad Sci USA 95 (1998) 9155-9160
24. Morohashi K., Yoshino A., Yoshimori A., Saito S., Tanuma S., Sakaguchi K., et al. Identification of a drug target motif: an anti-tumor drug NK109 interacts with a PNxxxxP. Biochem Pharmacol 70 (2005) 37-46
25. Rothbard J.B., Kreider E., VanDeusen C.L., Wright L., Wylie B.L., and Wender P.A. Arginine-rich molecular transporters for drug delivery: role of backbone spacing in cellular uptake. J Med Chem 45 (2002) 3612-3618
26. Auclair C., Voisin E., Banoun H., Paoletti C., Bernadou J., and Meunier B. Potential antitumor agents: synthesis and biological properties of aliphatic amino acid 9-hydroxyellipticinium derivatives. J Med Chem 27 (1984) 1161-1166
27. Lum B.L., Gosland M.P., Kaubisch S., and Sikic B.I. Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacotherapy 13 (1993) 88-109
28. Hendrikse N.H. Monitoring interactions at ATP-dependent drug efflux pumps. Curr Pharm Des 6 (2000) 1653-1668
29. Eastman A. Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J Cell Biochem 91 (2004) 223-231
30. Barratt R.A., Kao G., McKenna W.G., Kuang J., and Muschel R.J. The G2 block induced by DNA damage: a caffeine-resistant component independent of Cdc25C, MPM-2 phosphorylation, and H1 kinase activity. Cancer Res 58 (1998) 2639-2645
31. Castedo M., Perfettini J.L., Roumier T., Andreau K., Medema R., and Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 23 (2004) 2825-2837
32. Hyzy M., Bozko P., Konopa J., and Skladanowski A. Antitumour imidazoacridone c-1311 induces cell death by mitotic catastrophe in human colon carcinoma cells. Biochem Pharmacol 69 (2005) 801-809
33. Michels J., Johnson P.W., and Packham G. Mcl-1. Int J Biochem Cell Biol 37 (2005) 267-271